Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.48 |
| ▸ | ACACB | O00763 | 6/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | ACACA | Q13085 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324220 | 0.86 | MMP13 (0.45) | MMP13OPRM1 | |
| SCHEMBL6323384 | 0.85 | MMP13 (0.67) | MMP13ACACBOPRM1OPRD1OPRK1 | |
| SCHEMBL6325865 | 0.84 | MMP13 (0.52) | MMP13 | |
| SCHEMBL6327554 | 0.84 | MMP13 (0.67) | MMP13 | |
| SCHEMBL6332792 | 0.84 | MMP13 (0.47) | MMP13ACACBOPRM1OPRD1OPRK1 | |
| SCHEMBL6333651 | 0.83 | MMP13 (0.55) | MMP13ACACBOPRM1OPRD1OPRK1 | |
| SCHEMBL6326831 | 0.83 | MMP13 (0.68) | MMP13ACACB | |
| SCHEMBL6333055 | 0.81 | MMP13 (0.67) | MMP13ACACBOPRM1ACACA | |
| SCHEMBL6327805 | 0.80 | MMP13 (0.68) | MMP13ACACBACACA | |
| SCHEMBL6325828 | 0.79 | MMP13 (0.61) | MMP13ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159413-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | NOE MARK C (US) | 2005-07-21 | — | — | US | disclosed |
| US-6841671-B2 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1332146-A2 | SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096803-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2002034753-A2 | SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096803-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, TIMP3, MMP2 | MMP13 39/4885ACACB 2464/4885OPRM1 4335/4885 |
| US-20050159413-A1 | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, TIMP3, MMP8 | MMP13 34/4885ACACB 2290/4885OPRM1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.